ESTRAGYN DIN 00287725
Health Canada record
| Active ingredient(s) | ESTERIFIED ESTROGENS 0.625 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | G03CA NATURAL AND SEMISYNTHETIC ESTROGENS, PLAIN |
| Original market date | 31-Dec-1974 |
| Current status date | 18-Jul-2024 |
| Source | Health Canada DPD |
Establishment licence of the holder
Searchlight Pharma Inc — licence 102247, currently licensed, last inspection rating C (2024-10-10).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing ESTERIFIED ESTROGENS
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 00473618 | ESTRAGYN | SEARCHLIGHT PHARMA INC | Tablet | ESTERIFIED ESTROGENS 0.3 MG | Cancelled Post Market |
| 00287733 | NEO ESTRONE TAB 1.25MG | NEOLAB INC | Tablet | ESTERIFIED ESTROGENS 1.25 MG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 16955 | 2015-06-01 | New Drug Submission (NDS) | TRANSFER OF DRUG IDENTIFICATION NUMBERS |
| 16278 | 2014-11-13 | New Drug Submission (NDS) | TRANSFER OF DRUG IDENTIFICATION NUMBERS |
| 15630 | 2014-05-23 | New Drug Submission (NDS) | TRANSFER OF DRUG IDENTIFICATION NUMBERS |
| 11725 | 2010-09-21 | New Drug Submission (NDS) | Manufacturer and product name change |
International API supply for ESTERIFIED ESTROGENS
2 active FDA Drug Master Files.
Request a quote for ESTRAGYN